> Pharming began a phase 1/2 trial of its recombinant human C1 esterase inhibitor in patients with pre-eclampsia. The trial is scheduled to deliver data in the third quarter of 2020. Release
> Oncurious received a grant from Flanders Innovation and Entrepreneurship to support preclinical development of its cancer immunotherapies. The Belgian biotech hopes to identify and test multispecific biologics. Statement
> Galapagos and Servier completed enrollment in a phase 2 osteoarthritis trial. The trial is assessing the effect of 52 weeks of treatment with ADAMTS-5 inhibitor GLPG1972. Release
> A phase 2b trial of NeRRe Therapeutics’ orvepitant missed its primary endpoint. The neurokinin-1 receptor antagonist was no better than placebo at reducing awake cough frequency in refractory chronic cough. Statement
> Pfizer picked a clinical candidate from its collaboration with Sosei Heptares, triggering a $3 million (€2.7 million) milestone payment. The candidate is the second picked by Pfizer in as many months. Release
> Immunicum posted phase 1/2 data on its lead candidate in gastrointestinal stromal tumors. Release